Sichuan Biokin Pharmaceutical Co.,Ltd. (SHA:688506)
China
· Delayed Price · Currency is CNY 283.50
-8.01 (-2.75%)
At close: Apr 23, 2025, 2:57 PM CST
SHA:688506 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Operating Revenue | 5,823 | 560.42 | 701.83 | 794.95 | 1,011 | Upgrade
|
| Other Revenue | - | 1.46 | 1.45 | 1.78 | 1.66 | Upgrade
|
| Revenue | 5,823 | 561.87 | 703.28 | 796.73 | 1,013 | Upgrade
|
| Revenue Growth (YoY) | 936.31% | -20.11% | -11.73% | -21.33% | -16.07% | Upgrade
|
| Cost of Revenue | 264.39 | 242.26 | 237.7 | 203.39 | 202.02 | Upgrade
|
| Gross Profit | 5,558 | 319.61 | 465.58 | 593.34 | 810.69 | Upgrade
|
| Selling, General & Admin | 405.04 | 367.89 | 403.01 | 467.46 | 636.86 | Upgrade
|
| Research & Development | 1,443 | 746.23 | 375.02 | 278.6 | 195.7 | Upgrade
|
| Other Operating Expenses | -33.15 | -2.27 | 9.79 | 9.17 | 3 | Upgrade
|
| Operating Expenses | 1,815 | 1,105 | 795.41 | 752.86 | 833.55 | Upgrade
|
| Operating Income | 3,744 | -785.6 | -329.83 | -159.52 | -22.85 | Upgrade
|
| Interest Expense | - | -24.68 | -22.48 | -8.69 | -7.57 | Upgrade
|
| Interest & Investment Income | 19.23 | 5.71 | 0.77 | 3.61 | 4.75 | Upgrade
|
| Currency Exchange Gain (Loss) | - | -1.11 | -0.05 | -0.14 | - | Upgrade
|
| Other Non Operating Income (Expenses) | 223.17 | -0.84 | -0.56 | -0.35 | 0.02 | Upgrade
|
| EBT Excluding Unusual Items | 3,986 | -806.51 | -352.16 | -165.09 | -25.66 | Upgrade
|
| Gain (Loss) on Sale of Investments | 11.44 | - | - | - | 0.34 | Upgrade
|
| Gain (Loss) on Sale of Assets | -0 | -0.14 | -0.48 | -0.45 | - | Upgrade
|
| Asset Writedown | -19.35 | - | - | - | -0.17 | Upgrade
|
| Other Unusual Items | - | 37.64 | 63.57 | 61.1 | 71.11 | Upgrade
|
| Pretax Income | 3,978 | -769.01 | -289.07 | -104.44 | 45.62 | Upgrade
|
| Income Tax Expense | 270.65 | 11.49 | -6.69 | -4.45 | 7.7 | Upgrade
|
| Earnings From Continuing Operations | 3,708 | -780.5 | -282.38 | -99.99 | 37.92 | Upgrade
|
| Minority Interest in Earnings | - | - | - | - | -0.02 | Upgrade
|
| Net Income | 3,708 | -780.5 | -282.38 | -99.99 | 37.9 | Upgrade
|
| Net Income to Common | 3,708 | -780.5 | -282.38 | -99.99 | 37.9 | Upgrade
|
| Net Income Growth | - | - | - | - | 390.26% | Upgrade
|
| Shares Outstanding (Basic) | 401 | 400 | 362 | 357 | 345 | Upgrade
|
| Shares Outstanding (Diluted) | 401 | 400 | 362 | 357 | 345 | Upgrade
|
| Shares Change (YoY) | 0.14% | 10.56% | 1.38% | 3.64% | -10.86% | Upgrade
|
| EPS (Basic) | 9.25 | -1.95 | -0.78 | -0.28 | 0.11 | Upgrade
|
| EPS (Diluted) | 9.25 | -1.95 | -0.78 | -0.28 | 0.11 | Upgrade
|
| EPS Growth | - | - | - | - | 450.00% | Upgrade
|
| Free Cash Flow | 3,975 | -697.29 | -293.21 | -179.63 | 63.09 | Upgrade
|
| Free Cash Flow Per Share | 9.92 | -1.74 | -0.81 | -0.50 | 0.18 | Upgrade
|
| Gross Margin | 95.46% | 56.88% | 66.20% | 74.47% | 80.05% | Upgrade
|
| Operating Margin | 64.29% | -139.82% | -46.90% | -20.02% | -2.26% | Upgrade
|
| Profit Margin | 63.67% | -138.91% | -40.15% | -12.55% | 3.74% | Upgrade
|
| Free Cash Flow Margin | 68.26% | -124.10% | -41.69% | -22.55% | 6.23% | Upgrade
|
| EBITDA | 3,812 | -727.7 | -272.27 | -109.37 | 26.45 | Upgrade
|
| EBITDA Margin | 65.46% | -129.51% | -38.71% | -13.73% | 2.61% | Upgrade
|
| D&A For EBITDA | 68.03 | 57.9 | 57.56 | 50.16 | 49.31 | Upgrade
|
| EBIT | 3,744 | -785.6 | -329.83 | -159.52 | -22.85 | Upgrade
|
| EBIT Margin | 64.29% | -139.82% | -46.90% | -20.02% | -2.26% | Upgrade
|
| Effective Tax Rate | 6.80% | - | - | - | 16.87% | Upgrade
|
| Revenue as Reported | - | 561.87 | 703.28 | 796.73 | 1,013 | Upgrade
|
Updated Feb 27, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.